Clinical Trial

Ph2 Open-label Study of AOC 1044 in Duchenne Muscular Dystrophy Participants With Mutations Amenable to Exon44 Skipping

Study acronym: EXPLORE44OLE
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
AOC 1044-CS2 (EXPLORE44-OLE) is an Open-label Study to Evaluate the Long-Term Safety and Tolerability of AOC 1044 Administered Intravenously to DMD Participants with Mutations Amenable to Exon 44 Skipping.
Protocol Amendment History 1 change
minor Completion moved earlier: 2027-07-31 -> 2027-04-30 2026-07-31
Trial Details
NCT Number NCT06244082
Lead Sponsor Avidity Biosciences, Inc.
Conditions DMD, Duchenne Muscular Dystrophy, Duchenne, Exon 44
Enrollment 39 participants
Start Date 2024-01-22
Primary Completion 2027-04-30 (estimated)
Study Completion 2027-04-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-30